Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma

Inclusion Criteria: * Patients must have histologically confirmed soft tissue sarcoma with evidence of metastatic or unresectable disease. * Patients must have measurable disease by RECIST 1.1. * Up to 32 prior cytotoxic chemotherapy regimens in the metastatic setting are allowed. Adjuvant chemotherapy or targeted therapy will not be considered a prior line of treatment. * Age ≥18 years. * ECOG performance status ≤2 (Karnofsky ≥60%). * Life expectancy of greater than 12 weeks. * Patients must have normal organ and marrow function as defined below: * leukocytes ≥3,000/µL * absolute neutrophil count ≥1,500/µL * platelets ≥100,000/µL * total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT) ≤1.5 X institutional upper limit of normal (ULN) * creatinine ≤1.5 X institutional upper limit of normal (ULN) * Peripheral neuropathy, if present, should be ≤grade 1. * Women of Child bearing potential MUST use contraceptives. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * The following specific histologic subtypes of soft tissue sarcomas will be excluded: GIST, Kaposi's sarcoma, mesothelioma, dermatofibrosarcoma, chordoma, alveolar soft-part sarcoma. Also, all bone sarcomas are excluded including Ewing's sarcoma, osteosarcoma, GIST, low grade chondrosarcoma, and chordoma. * Patients who have had treatment with chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to starting study treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * Patients who are receiving any other investigational agents. * Patients with known brain metastases. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, docetaxel, vorinostat, or G-CSF. * Patients who have received and progressed on the combination of gemcitabine and docetaxel in the metastatic setting. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant and breastfeeding women * Patients taking concomitant HDAC inhibitors. * HIV-positive patients on combination antiretroviral treatment